Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC	Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 2	2026-07-14		NCT07703228

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Cancer Hospital & Institute of Guangzhou Medical University	33
Department of Obstetrics and Gynecology, Affiliated Dongguan People's Hospital, Southern Medical University	1
Nanfang Hospital, Southern Medical University	248
Shenzhen Hospital of Guangzhou University of Chinese Medicine	1
The Central Hospital of Huanggang	5

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Nanfang Hospital of Southern Medical University	Guangzhou	China	37